Abstract
Purpose: To evaluate the efficacy and safety of intravitreal injection of bevacizumab without laser as primary therapy in patients with threshold disease in difficulties or lack of facilities for laser as Al Qassim region. Patients and methods: The study included eighteen eyes of nine patients with moderate to severe active ROP (stage III, threshold, or plus disease in zones I and II). For all we gave intravitreal injection of bevacizumab without laser after obtained written consent from the parents, including disclosure of the off-label use of the drug, its unknown safety and efficacy for this indication, and its unknown effects in children. Results: Of 18 eyes enrolled in the study, all have completed 1-year follow-up. Mean birth weight in these infants was 1235 gm, mean gestational age at birth was 28.8 weeks, and mean age at the time of injection was 1.5 months. All eyes showed complete resolution of neovascular plus disease. No patient developed any ocular or systemic complications. In all cases, the ERG and VEP were within normal at 1 year. Conclusions: Intravitreal injection of bevacizumab is an easy, safe and effective modality of therapy for threshold disease ROP especially in presence of difficulties for laser photocoagulation.
Highlights
Of 18 eyes enrolled in the study, all have completed 1-year follow-up
It has been shown that serum Vascular endothelial growth factor (VEGF) levels are elevated in cases of Retinopathy of prematurity (ROP)
It is thought that VEGF is responsible for an increase in vascular permeability, the suppression of genetically programmed endothelial cell apoptosis and the promotion of neovascularization in ROP
Summary
The study included eighteen eyes of nine patients with moderate to severe active ROP (stage III, threshold, or plus disease in zones I and II). For all we gave intravitreal injection of bevacizumab without laser after obtained written consent from the parents, including disclosure of the off-label use of the drug, its unknown safety and efficacy for this indication, and its unknown effects in children. This prospective non randomized study included eighteen eyes of nine patients with moderate to severe active ROP (stage III, threshold, or plus disease in zones I and II). Exclusion criteria were refusal of informed consent from a parent or guardian, any previous laser, cryo or surgical procedure and presence of traction (stage IV)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
More From: Journal of Clinical & Experimental Ophthalmology
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.